Takeda Pharmaceutical is focused on metabolic disorders, gastroenterology, neurology, inflammation, as well as oncology through its independent subsidiary, Takeda Oncology.
| FactSnippet No. 1,400,253 |
18 Facts About Takeda Pharmaceutical
2.
In February 2005, Takeda Pharmaceutical acquired San Diego, California, based Syrrx, a company specializing in high-throughput X-ray crystallography, for US$270 million.
| FactSnippet No. 1,400,254 |
3.
In February 2008, Takeda Pharmaceutical acquired the Japanese operations of Amgen and rights to a dozen of the California biotechnology company's pipeline candidates for the Japanese market.
| FactSnippet No. 1,400,255 |
4.
In May 2012, Takeda purchased Brazilian pharmaceutical company Multilab for R$540 million.
| FactSnippet No. 1,400,256 |
5.
In September 2014, Takeda Pharmaceutical announced it would team up with BioMotiv to identify and develop new compounds over a five-year period, worth approximately US$25 million.
| FactSnippet No. 1,400,257 |
6.
On 30 September 2014, Takeda Pharmaceutical announced it would expand a collaboration with MacroGenics, valued up to US$1.
| FactSnippet No. 1,400,258 |
7.
In 2015, Takeda Pharmaceutical sold its respiratory drugs business to AstraZeneca for $575 million, which included roflumilast and ciclesonide.
| FactSnippet No. 1,400,259 |
8.
In January 2020, Takeda Pharmaceutical announced a research partnership with the Massachusetts Institute of Technology to advance discoveries in artificial intelligence and health.
| FactSnippet No. 1,400,260 |
9.
In March 2020, Takeda announced that it has entered into an exclusive agreement to divest a portfolio of non-core products in Latin America to Hypera S A for a total value of $825 million.
| FactSnippet No. 1,400,261 |
10.
In 1977, Takeda first entered the U S pharmaceutical market by developing a joint venture with Abbott Laboratories called TAP Pharmaceuticals.
| FactSnippet No. 1,400,262 |
11.
In May 2019, Takeda Pharmaceutical sold its Xiidra dry-eye drug business to Novartis for $5.
| FactSnippet No. 1,400,263 |
12.
In November 2019, Takeda Pharmaceutical entered an agreement to sell its over-the-counter and prescription drugs businesses in Russia, Georgia, Armenia, Azerbaijan, Belarus, Kazakhstan, and Uzbekistan to Stada Arzneimittel for $660 million.
| FactSnippet No. 1,400,264 |
13.
In June 2020, Takeda Pharmaceutical announced that it was divesting 18 over-the-counter and prescription drugs marketed in the Asia-Pacific region to South Korea's Celltrion in a deal worth $278 million.
| FactSnippet No. 1,400,265 |
15.
Takeda Pharmaceutical maintains research and development sites in Japan, the United States, the United Kingdom and Singapore, with manufacturing facilities across the globe.
| FactSnippet No. 1,400,267 |
16.
Takeda Pharmaceutical said the decision is expected to resolve the “vast majority” of these cases.
| FactSnippet No. 1,400,268 |
17.
In 2014, a plaintiff was awarded $9 billion in punitive damages after a federal court found Takeda Pharmaceutical hid the cancer risks of their diabetes medicine, but the amount was later reduced to $26 million by a judge who deemed the charge excessive.
| FactSnippet No. 1,400,269 |
18.
Takeda Pharmaceutical is a corporate partner of Human Rights Campaign, a large LGBT advocacy organization.
| FactSnippet No. 1,400,270 |